Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — 15th Annual Australian Microcap Investment Conference 2026
27 slides from Neurizon Therapeutics's conference presentation, May 11, 2026
Slide 1: Australian Microcap Investment Conference presentation
Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Australian Microcap Investment Conference presentation 11 May 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to adv
Slide 2: About Neurizon Therapeutics Limited
Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, N
Slide 3: A promising new horizon in neurodegenerative diseases
For personal use only Neurizon Therapeutics A promising new horizon in neurodegenerative diseases John Clark, Chief Operating Officer Australian Microcap Investment Conference May 2026, Sydney ABN 35 094 006 023
Slide 4: Disclaimer
Disclaimer For personal use only This disclaimer applies to this presentation and the information contained in it (This presentation has been Future Matters prepared by Neurizon Therapeutics Limited (ASX: NUZ) (the “Company”)). It does not purport to contain all the information that a prospective in
Slide 5: Our Vision
For personal use only Our Vision To lead the development of neurodegenerative treatments towards a promising new horizon for patients.
Slide 6: Our Promise
Accelerating Patient Driving Access to Innovative ALS Clinical For personal use only Our Promise Treatment Progress Unlocking the potential Delivering commercial of Neurizon to address readiness and high unmet need in stakeholder neurodegenerative value diseases
Slide 7: Neurizon: From Scientific Origin to Clinical Momentum
Neurizon: From Scientific Origin to Clinical Momentum A unique opportunity in neurodegenerative diseases Well characterised drug Disease-modifying potential Strong foundation Late-stage clinical execution For personal use only 1 2 3 4 5 DISCOVERY & FOUNDATION TRANSLATION TO HUMAN DISEASE NEURIZON FO
Slide 8: NUZ-001: Potential application to range of neurodegenerative diseases
NUZ-001: Potential application to range of neurodegenerative diseases ALS is a current priority, but NUZ-001 has potential application to a range of neurodegenerative diseases. For personal use only NUZ-001 is a mechanism-driven, disease-agnostic approach to treating New preclinical data show NUZ-00
Slide 9: HEALEY Trial: Opportunity for accelerated approval
HEALEY Trial: Opportunity for accelerated approval Initial focus is ALS, a rare disease with high unmet need and the possibility of accelerated approval on Phase 2/3 data. Potential for broader application being developed through pre-clinical program. For personal use only Drug / Approved/ Indicatio
Slide 10: Phase 1 ALS MEND Study and Open Label Extension: Early Signals of Efficacy
For personal use only Phase 1 ALS MEND Study and Open Label Extension Early Signals of Efficacy
Slide 11: Preliminary Efficacy ALSFRS-R and SVC
Phase 1 Open Label Extension Preliminary Efficacy ALSFRS-R and SVC Treatment with NUZ-001 across combined Phase 1 and OLE studies slowed the progression of ALS in all patients by 31% for ALSFRS-R and 43% for SVC percent For personal use only predicted (PP) when compared to matched controls from the
Slide 12: Survival Probability Analysis
Phase 1 Open Label Extension Survival Probability Analysis For personal use only Compared to matched controls from the PRO-ACT database, treatment with NUZ-001 results in significantly longer survival of patients with ALS (X2=10.95, p=0.00094) . Analysis Method Log-Rank Test Cox Proportional Hazards
Slide 13: Safety and Tolerability Summary
Phase 1 Open Label Extension Safety and Tolerability Summary For personal use only Study drug was shown to be safe and generally well tolerated during long-term administration in the OLE, with no dose-limiting toxicities and no treatment-related deaths. Total (n) Related to Treatment (n) Adverse Eve
Slide 14: Registrational Phase 2/3 HEALEY ALS Platform Trial
For personal use only Registrational Phase 2/3 HEALEY ALS Platform Trial
Slide 15: HEALEY ALS Platform Trial Regimen 'I' for NUZ-001
HEALEY ALS Platform Trial Regimen ‘I’ for NUZ-001 36-week Double Blind Placebo 36-week Active Treatment Controlled Period Extension Period For personal use only NUZ-001 10 mg/kg Inclusion/Exclusion Criteria 3:1 Randomisation NUZ-001 n=160 participants 10 mg/kg Placebo Primary Endpoint • Change from
Slide 16: Regimen-I HEALEY ALS Platform Trial Expected Key Milestones
‘Regimen-I’ HEALEY ALS Platform Trial Expected Key Milestones Q4 2025 Q4 2025 Q1 2026 Q1 2026 Q3-Q4 2026 Q2-Q3 2027 Q3 2027 Q3 2027 For personal use only 5 6 7 8 IND Amendment FDA First Patient First Patient Dosed Enrollment Last Patient Database Topline Data Submission Clearance Screened Complete D
Slide 17: Strong Recruitment Momentum
Strong Recruitment Momentum For personal use only 59 62 Activated Sites Regimen Assignment 123 48 Master Screening Dosed Participants Numbers referred to above are as of 5 May 2026. Australian Microcap Investment Conference 15
Slide 18: Investment Potential
For personal use only Investment Potential
Slide 19: HEALEY: Funding secured
HEALEY: Funding secured Strong shareholder support has secured adequate funding for HEALEY ALS Platform trial1 Neurizon’s funding strategy has been developed with a focus on protecting shareholders’ interests through flexible funding instruments and minimising dilution. This includes the ability to
Slide 20: ALS: High Unmet Need with Significant Value Potential
ALS: High Unmet Need with Significant Value Potential A serious, rapidly progressive disease with limited treatment options. Meaningful innovation in ALS can create value for people living with ALS and the market. For personal use only THE NEED IN ALS WHY NUZ-001 IS RELEVANT COMMERCIAL VALUE POTENTI
Slide 21: ALS: Multiple large-value transactions and deals in recent years
ALS: High Unmet Need with Significant Value Potential Multiple large-value transactions and deals in recent years For personal use only Key ALS Value Reference Point: Shionogi – RADICAVA US$2.5B Transaction Other Recent ALS Deals (April 2026)1 Eli Lilly entered neurodegenerative disease collaboratio
Slide 22: NUZ-001: Strong portfolio protection
NUZ-001: Strong portfolio protection In addition to patent protection, NUZ-001 has US Orphan Drug Designation (ODD) and European Orphan Medicinal Product Designation (OMPD) providing 7 and 10 years of market exclusivity, respectively. For personal use only Patent Families for monepantel 2020 2030 20
Slide 23: NUZ-001 Regulatory Strategy for ALS Market Access
NUZ-001 Regulatory Strategy for ALS Market Access Orphan Drug Designation For personal use only FDA Q2 Q3 Q3 H1 2024 2025 2026 2028 IND Clearance Type C Meeting NDA Submission Orphan Drug Designation EMA Q4 Q3 H1 2024 2026 2028 Scientific Protocol Advice Meeting MAA Submission General Consulta
Slide 24: Demonstrating Meaningful Progress
Demonstrating Meaningful Progress For personal use only Executed Global Regimen “I” Successful Secured registered Promising Australian License commenced in the manufacture of trademark exploratory top- Patent granted Agreement with HEALEY ALS three registration protection for line results from for N
Slide 25: What Comes Next in Our Growth Strategy
What Comes Next in Our Growth Strategy Our Focus Areas: Potential Value Outcomes: For personal use only Ongoing clinical execution Clinical de-risking driving higher probability of success Continued data generation High-quality data generating long-term value Progressing the Regulatory Pathway Regul
Slide 26: For personal use only
“ ~S Neurizon. <% "a j an “wg
Slide 27: Thank you
For personal use only THANK YOU Registered Address: Suite 2, Level 11, 385 Bourke Street Melbourne, VIC 3000 Australia +61 (3) 9692 7222 enquiries@neurizon.com
Neurizon Therapeutics — 15th Annual Australian Microcap Investment Conference 2026 on 6ix